Use of kinase inhibitor for the treatment of thymoma

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8580793
APP PUB NO 20120077819A1
SERIAL NO

13256467

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention provides a low molecular weight ATP-competitive CDK inhibitor and TRKA inhibitor of formula (I) for use in the treatment of thymoma and thymic carcinoma. The compound can be administered together with one or more cytotoxic or cytostatic agents.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
NERVIANO MEDICAL SCIENCES S R L20014 NERVIANO (MI)

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Ciomei, Marina Corsico, IT 21 226
Comis, Silvia Bubbiano, IT 2 0
Laffranchi, Bernard Bubbiano, IT 2 0
Pacciarini, Maria Adele Milan, IT 2 0
Scaburri, Angela Legnano, IT 2 57

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 12, 2025
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00